<?xml version="1.0" encoding="UTF-8"?>
<p>For PWUD in community settings, disruptions in global supply chains and implementation of physical distancing measures in response to the COVID‐19 pandemic may limit access to drugs and harm reduction services. The popular press has documented limited availability of fentanyl and other synthetic opioids due to closings of chemical manufacturing plants in Wuhan, China [
 <xref rid="jia225551-bib-0013" ref-type="ref">13</xref>]. Rising nationalism evidenced by policies banning pharmaceutical and PPE exports, such as those instituted by the United States and India [
 <xref rid="jia225551-bib-0014" ref-type="ref">14</xref>], and border closings, such as those implemented in South America [
 <xref rid="jia225551-bib-0015" ref-type="ref">15</xref>], may decrease the availability of certain drugs, including synthetic opioids. Whether disruptions in the drug supply chain are real or imagined, the fear experienced by PWUD has an immeasurable effect on their wellbeing. In addition, harm reduction programmes, including naloxone distribution and syringe exchange, have become increasingly difficult to access under “shelter in place” restrictions [
 <xref rid="jia225551-bib-0016" ref-type="ref">16</xref>].
</p>
